Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05975983 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
A Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF), sponsored by InSilico Medicine Hong Kong Limited.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 12
- Study locations
NCT05975983: Recruiting Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF), sponsored by InSilico Medicine Hong Kong Limited.
NCT05975983 is a Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF) that is actively recruiting participants, run by InSilico Medicine Hong Kong Limited. The registered enrollment target is 40 participants, below the 492-participant average among 8 other Idiopathic Pulmonary Fibrosis (IPF) trials with a reported enrollment target (92% lower). The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05975983, a Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF), is actively recruiting participants, sponsored by InSilico Medicine Hong Kong Limited.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this revised Phase IIa study is to demonstrate safety of INS018\_055 over 12 weeks in adults with Idiopathic Pulmonary Fibrosis (IPF).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG INS018_055
Study Locations (12)
Texas
- University of Texas Southwestern Medical Center - Dallas
- Metroplex Pulmonary and Sleep Center - McKinney
- Research Centers of America - McKinney
Florida
- Florida Lung Asthma and Sleep Specialist - Celebration
- Central Florida Pulmonary Group, P.A. (CFPG) - Downtown Orlando - Orlando
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- HonorHealth Research Institute - Scottsdale
California
- Keck School of Medicine of USC - Los Angeles
North Carolina
- Southeastern Research Center - Winston-Salem
Oklahoma
- University of Oklahoma Health Sciences Center (OUHSC) - Oklahoma City
Pennsylvania
- Temple University Hospital-Temple Lung Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-02-08 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 2 |
What NCT05975983 shows while recruiting
NCT05975983 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 492-participant average among 8 other Idiopathic Pulmonary Fibrosis (IPF) trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis (IPF) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05975983 lists 12 locations in 9 states (Texas, Florida, Alabama).
Frequently Asked Questions
What is clinical trial NCT05975983 about?
NCT05975983 is a clinical study titled "Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis". The purpose of this revised Phase IIa study is to demonstrate safety of INS018\_055 over 12 weeks in adults with Idiopathic Pulmonary Fibrosis (IPF).
What is the current status of trial NCT05975983?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-02-08. Estimated completion is 2026-02-28.
What conditions does trial NCT05975983 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis (IPF).
What interventions are being tested in trial NCT05975983?
The interventions under investigation include: Placebo (DRUG), INS018_055 (DRUG).
Who is sponsoring clinical trial NCT05975983?
This trial is sponsored by InSilico Medicine Hong Kong Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05975983 being conducted?
This trial has 12 study locations across Alabama, Arizona, California, Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis (IPF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05975983's enrollment target sits among peer trials
40 8th of 8 higher than 1 of 8 other Idiopathic Pulmonary Fibrosis (IPF) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis (IPF) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
RECRUITING · Phase 2
-
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
RECRUITING · Phase 2
-
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
COMPLETED · Phase 2
-
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
RECRUITING
-
The Genetics of Pulmonary Fibrosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI